



**Feng-Chi chen, PhD**

Investigator

+886-37-246166 ext. 36111

+886-37-586467

[fcchen@nhri.org.tw](mailto:fcchen@nhri.org.tw)

**Education**

- 1992  
B.S. in Biology,  
National Taiwan Normal University, Taiwan
- 2001  
Ph.D. in Life Sciences,  
National Tsing-Hua University, Taiwan
- 2019  
Master of Law,  
National Chiao Tung University, Taiwan

**Professional Experiences**

**Investigator**

**Institute of Population Health Sciences, National Health Research**

**Institutes**

**2016/04-present**

**Adjunct Professor**

**Department of Biological Science and Technology, National Chiao-Tung University**

**2016/09-present**

**Chairman, Committee of Information**

National Health Research Institutes

January 2019 – December 2021

**Chairman, Committee of Grievances**

National Health Research Institutes

October 2018 – September 2019

**Director, Computing and Information Center**

National Health Research Institutes

February 2017 – December 2018

**Adjunct Associate Professor**

School of Law, National Chiao-Tung University

September 2017 - February 2018

**Board of Directors, Taiwan Society of Evolutionary and Computational Biology**

September 2013- November 2016

**Committee of Intellectual Property Management**

National Health Research Institutes  
January 2016 – March 2017

### Research Interests

Patent Informatics; Quantitative Legal Analysis; Comparative Genomics and Transcriptomics; Molecular Evolution; Bioinformatics.

### Research Activities & Accomplishment

Over 50 scientific articles in international journals.  
National Health Research Institutes-Institutional Repository:

### Selected Publications

- **FC Chen\***, PS Lee, YY Huang, HC Wu, and HY Lin. 2019. Interactions between *Inter Partes* Review and Hatch-Waxman Litigations. ***Proceedings of 2019 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology***.
- **FC Chen\*** and Pin-Shen Lee. 2019. Inter Partes Review: patent killer no more? ***Trends in Biotechnology*** 37(7): 680-683.
- YH Yang, PJ Cheng\*, and **FC Chen\***. 2019. Predicting institution decisions in inter partes review proceedings. ***Journal of Patent and Trademark Office Society*** 100 (4): 697-717.
- **FC Chen\***. 2018. China: the next pharmacy of the world? ***Trends in Pharmacological Sciences*** 39 (10): 843-848.
- Pan CL and **Chen FC\***. 2017. Patent trend and competitive analysis of cancer immunotherapy in the United States. ***Human Vaccines and Immunotherapeutics*** 13(11):2583-2593.
- **Chen FC\*** and Guo-Liang Yeh. 2016. Invalidation of atorvastatin patent highlights complex Chinese patent law. ***Trends in Pharmacological Sciences*** 37(11):883-886..
- **Chen FC\***. 2016. Divided infringement in the limelight of the patent battle field. ***Trends in Biotechnology*** 34 (10): 771-773.
- Hsu MK, Pan CL, and **Chen FC\***. 2016. Functional divergence and convergence between the transcript network and gene network in lung adenocarcinoma. ***Oncotargets and Therapy*** 9: 335-347.
- Hsu MK, Wu IC, Cheng CC, Su JL\*, Hsieh CH, Lin YS, and **Chen FC\***. 2015. Triple-layer dissection of the lung adenocarcinoma transcriptome – regulation of the gene, transcript, and exon levels. ***Oncotarget*** 6(30):28755-73.
- **Chen FC\***. 2015. Alternative RNA structure-coupled translational regulations in tumorigenesis. ***International Journal of Molecular Sciences*** 16(1): 452-475. (invited review).

### Patent

None

